Education
About Us
Working with TipRanks
Follow Us
Control Bionics Ltd. (AU:CBL)
ASX:CBL
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.09
Previous CloseN/A
Volume65.91K
Average Volume (3M)173.99K
Market Cap
AU$22.66M
Enterprise ValueAU$18.34M
Total Cash (Recent Filing)AU$672.66K
Total Debt (Recent Filing)AU$435.40K
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Feb 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent double-digit top-line growth indicates durable demand for assistive-technology solutions. Over 2-6 months this supports scale economies, product adoption, and market penetration in a niche healthcare segment, improving the company's ability to leverage fixed costs and invest in commercialization.
Healthy Gross Profit MarginsSustained gross margins reflect favorable product economics and pricing power versus variable costs. This provides structural room to cover operating expenses and fund R&D or sales expansion, making margin improvement achievable as revenue scales and fixed-cost absorption improves.
Conservative Capital StructureA low leverage profile and strong equity financing reduce solvency risk and preserve financial flexibility. This durable balance-sheet strength supports continued R&D and commercialization efforts, and lowers the probability of distress financing during multi-quarter investment cycles.
Bears Say
Persistent Net LossesOngoing net losses signal that operating expenses and overhead outpace gross profit, limiting internal funding for growth. Persisting losses over multiple quarters weaken the firm's ability to reinvest, may require repeated external financing, and question long-term sustainability of current business operations.
Negative Operating Cash Flow / Weak FCFNegative operating cash flow and declining free cash flow show poor conversion of revenues into cash. This structural cash burn reduces runway, increases reliance on capital raises, and constrains the company's ability to fund product development, sales expansion, or cover unexpected shocks without dilutive financing.
Negative Return On EquityA negative ROE indicates shareholder capital is not producing positive returns, reflecting inefficient capital deployment or persistent losses. Over the medium term this undermines investor confidence and suggests management must materially improve margins or capital allocation to create lasting shareholder value.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.09 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$22.66M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Feb 25, 2026 which is in 5 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Aug 28, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 411,961,880 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
-103.74%
Trailing 12-Months
Asset Growth
-8.80%
Trailing 12-Months
Company Description
Control Bionics Ltd.
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.
Technical Analysis
Uscom Limited
―
HeraMED Ltd.
―
Atomo Diagnostics Ltd.
―
Adherium Ltd.
―
InhaleRx Limited
―
Options Prices
Currently, No data available
---